Effects of efonidipine hydrochloride, a calcium antagonist derived from dihydropyridine, on acute myocardial ischemia in anesthetized open-chest dogs

Folia Pharmacologica Japonica

Volumn 108, Issue 6, 1996, Pages 307-321

  Yokoyama, Tatsuro ^a   Fujikura, Naoki ^a   Masuda, Yukinori ^a   Shikada, Ken Ichi ^a   Tanaka, Sakuya ^a  

^a NISSAN CHEMICAL INDUSTRIES LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ANTAGONIST; DIHYDROPYRIDINE DERIVATIVE; EFONIDIPINE; NIFEDIPINE; NISOLDIPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; DOG; DRUG EFFECT; DRUG SCREENING; HEART MUSCLE ISCHEMIA; HEART OUTPUT; INTRAVENOUS DRUG ADMINISTRATION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; NONHUMAN; VASCULAR RESISTANCE;

EID: 0029845429     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.108.6_307     Document Type: Article

References (24)

1. Kern MJ: Perspective: the cellular influences of calcium antagonists on systemic and coronary hemodynamics. Am J Cardiol 69, 3B-7B (1992)
2. Yamashita T, Masuda Y, Sakai T, Tanaka S and Kasuya Y: NZ-105, a new 1, 4-dihydropyridine derivative: correlation between dihydropyridine receptor binding and inhibition of calcium uptake in rabbit aorta. Jpn J Pharmacol 57, 337-348 (1991)
3. Masuda Y and Tanaka S: Efonidipine hydrochloride: a new calcium antagonist. Cardiovasc Drug Rev 12, 123-135 (1994)
4. Masuda Y, Takeguchi M, Arakawa C, Sakai T, Hibi M, Tanaka S, Shigenobu K and Kasuya Y: Antihypertensive and diuretic effects of NZ-105, a novel dihydropyridine derivative. Arch Int Pharmacodyn Ther 304, 247-264 (1990)
5. Shudo C, Masuda Y, Sakai T, Tanaka S, Shigenobu K and Kasuya Y: Studies on the hypotensive mechanisms of NZ-105, a new dihydropyridine derivative, in rats and rabbits. Gen Pharrnacol 24, 411-418 (1993)
6. Dihydropyridine (±)-2-[benzyl (phenyl) amino] ethyl 1, 4-dihydro-2, 6-dimethyl-5-(5, 5-dimethyl-2-oxo-1, 3, 2-dioxaphosphorinan-2-yl)-4-(3-nitrophenyl)-3-pyridinecarboxylate hydrochloride ethanol (NZ-105) 42, 43-54 (1991)
7. (±)-2-[benzyl(phenyl)amino]ethyl 1, 4-dihydro-2, 6-dimethyl-5-(5, 5-dimethyl-2-oxo-1, 3, 2-dioxaphosphorinan-2-yl)-4-(3-nitrophenyl)-3-pyridinecarboxylate hydrochloride ethanol (NZ-105) 42, 55-60 (1991)
8. Gross GJ, Warltier DC and Hardman HF: Comparative effects of FR 34235, a new slow channel calcium blocker, and nifedipine on hemodynamics and myocardial oxygen consumption in the anesthetized dogs. Gen Pharmacol 14, 677-680 (1983)
9. Takahashi K and Taira N: Cardiovascular profiles of the calcium antagonists nisoldipine and nifedipine in the blood-perfused dog heart. Arzneimittelforschung 36, 1054-1059 (1986)
10. Braunwald E: Mechanism of action of calcium-channel-blocking agents. N Engl J Med 307, 1618-1627 (1982)
11. 2+ and heart function after ischemia. Am J Physiol 238, H909-H916 (1980)
12. Bush LR, Romson JL, Ash JL and Benedict LR: Effect of diltiazem on extent of ultimate myocardial injury resulting from temporary coronary occlusion in dogs. J Cardiovasc Pharmacol 4, 285-296 (1981)
13. Taira N: Difference in cardiovascular profile among calcium antagonist. Am J Cardiol 59, 24B-29B (1987)
14. Warltier DC, Zyvoloski MG, Gross GJ and Brooks HL: Comparative actions of dihydropyridine slow channel calcium blocking agents in conscious dogs; systemic and coronary hemodynamics with and without combined beta adrenergic blockade. J Pharmacol Exp Ther 230, 367-375 (1984)
15. Masuda Y, Iwama T, Yamashita T, Sakai T, Hibi M, Tanaka S, Shigenobu K and Kasuya Y: Vasorelaxing and receptor binding properties of NZ-105, a novel dihydropyridine derivative, in isolated rabbit aorta. Arch Int Pharmacodyn Ther 312, 86-103 (1991)
16. Tanaka H, Masumiya H, Sekine T, Sijuku T, Sugawara M, Taniguchi H, Terada M, Saito W and Shigenobu K: Myocardial and vascular effects of efonidipine in vitro as compared with nifedipine, verapamil and diltiazem. Gen Pharmacol 27, 451-454 (1996)
17. Kazda S, Garthoff B, Meyer H, Schloßmann K, Stoepel K, Towart R, Vater W and Wehinger E: Pharmacology of a new calcium antagonistic compound, isobutyl methyl 1, 4-dihydro-2, 6-dimethyl-4-(2-nitrophenyl)-3, 5-pyridinedicarboxylate (nisoldipine, BAY k 5552). Arzneimittelforschung 30, 2144-2162 (1980)
18. Jolly SR, Hardman HF and Gross GJ: Comparison of two dihydropyridine calcium antagonists on coronary collateral blood flow in acute myocardial ischemia. J Pharmacol Exp Ther 217, 20-25 (1981)
19. Beaughard M, Michelin MT, Tisne-Versailles J and Lamar JC: Comparative effects of bepridil, diltiazem, nifedipine and verapamil on haemodynamic parameters and myocardial oxygen consumption in anaesthetized dogs. Arch Int Pharmacodyn Ther 284, 276-296 (1986)
20. Toribatake T, Fujii K, Kobayashi M, Okumura M and Aikawa K: Pharmacological studies of a newly synthesized 1, 4-dihydropyridine derivative, 2, 6-dimethyl-3, 5-dimethoxycarbonyl-4-(o-difluoromethoxyphenyl) - 1, 4 - dihydropyridine (PP-1466). Arzneimittelforschung 35, 680-686 (1985)
21. pranidipine (OPC-13340) 103, 101-109 (1994)
22. Buxton DB, Mody FV, Krivokapich J, Phelps ME and Schelbert HR: Quantitative assessment of prolonged metabolic abnormalities in reperfused canine myocardium. Circulation 85, 1842-1856 (1992)
23. Shulz W, Jost S, Kober G and Kaltenbach M: Relation of antianginal efficacy of nifedipine to degree of coronary arterial narrowing and to presence of coronary collateral vessels. Am J Cardiol 55, 26-32 (1985)